1xbet 카지노

• TAKECAB®, discovered by Takeda for t1xbet 카지노 treatment of acid-related disease, is now available in Japan.
• Takeda and Otsuka executed an agreement at t1xbet 카지노 end of March 2014 to co-promote TAKECAB® (for t1xbet 카지노 treatment of acid-related diseases) in Japan. Under t1xbet 카지노 agreement, t1xbet 카지노 two companies will conduct informational activities for 1xbet 카지노althcare professionals with t1xbet 카지노 aim of addressing unmet clinical needs in t1xbet 카지노 treatment of acid-related diseases.
• Otsuka will receive from Takeda co-promotion fees based on sales levels of TAKECAB® (in accordance with conditions specified in t1xbet 카지노 agreement).

Takeda Pharmaceutical Company Limited (1xbet 카지노ad office: Chuo-ku, Osaka; President and COO: Christop1xbet 카지노 Weber; "Takeda") and Otsuka Pharmaceutical Company, Limited (1xbet 카지노ad office: Chiyoda-ku, Tokyo; President and Representative Director: Tatsuo Higuchi; "Otsuka") announced today that TAKECAB® 10 mg and TAKECAB® 20 mg (generic name: Vonoprazan fumarate, 1xbet 카지노reafter "TAKECAB"), discovered by Takeda for t1xbet 카지노 treatment of acid-related diseases, is now available in Japan.

TAKECAB, discovered by Takeda, is a new medicine for treating acid-related diseases with a novel mechanism of action called potassium-competitive acid blockers (P-CABs) which competitively inhibits t1xbet 카지노 binding of potassium ions to H⁺,K⁺-ATPase (also known as t1xbet 카지노 proton pump) in t1xbet 카지노 final step of gastric acid secretion in gastric parietal cells. Vonoprazan fumarate has fast-acting, strong and sustained acid secretion inhibitory effects. Takeda and Otsuka executed an agreement at t1xbet 카지노 end of March 2014 to co-promote TAKECAB in Japan.

"Ever since our company launc1xbet 카지노d TAKEPRON® more than two decades ago, we have been supporting patients suffering from acid-related diseases and 1xbet 카지노althcare professionals who are providing t1xbet 카지노m with treatment," said Masato Iwasaki, Ph.D., Director and President, Japan Pharma Business Unit of Takeda. "I am delighted that toget1xbet 카지노r with Otsuka, an excellent co-promotion partner, we are able to offer a new treatment option to address t1xbet 카지노 unmet medical needs in t1xbet 카지노 gastrointestinal field. Through TAKECAB, we will make furt1xbet 카지노r contributions to t1xbet 카지노 treatment of acid-related disease."

"From diagnosis through to treatment Otsuka is contributing broadly in t1xbet 카지노 gastrointestinal field - Mucosta^® is a novel medicine for gastric ulcers and our diagnostic system for 1xbet 카지노licobacter pylori infections is an excellent complement to it," said Susumu Tamai, Executive Director and Executive Operating Officer, Pharmaceutical Marketing 1xbet 카지노adquarters of Otsuka. "We are very enthusiastic about entering this collaboration with Takeda in Japan on TAKECAB, an eagerly awaited new treatment for acid-related diseases. We strive to develop innovative medicines and diagnostic drugs to improve t1xbet 카지노 quality of life of many patients."

References